Verseon Diabetic Retinopathy Program

Verseon Diabetic Retinopathy Program Successfully Passes Important in vivo Test of Drug Efficacy

Study strongly suggests that VE-4840 mitigates damage to retinal blood vessels and is also a milestone in establishing the compound’s effectiveness as an oral treatment of diabetic retinopathy